Characterization of a pluripotent stem cell-derived matrix with powerful osteoregenerative capabilities

Eoin P. McNeill, Suzanne Zeitouni, Simin Pan, Andrew Haskell, Michael Cesarek, Daniel Tahan, Bret H. Clough, Ulf Krause, Lauren K. Dobson, Mayra Garcia, Christopher Kung, Qingguo Zhao, W. Brian Saunders, Fei Liu, Roland Kaunas () and Carl A. Gregory ()
Additional contact information
Eoin P. McNeill: Texas A&M Health Science Center
Suzanne Zeitouni: Texas A&M Health Science Center
Simin Pan: Texas A&M Health Science Center
Andrew Haskell: Texas A&M Health Science Center
Michael Cesarek: Texas A&M Health Science Center
Daniel Tahan: Texas A&M Health Science Center
Bret H. Clough: Texas A&M Health Science Center
Ulf Krause: University Hospital Muenster
Lauren K. Dobson: Texas A&M University
Mayra Garcia: Texas A&M Health Science Center
Christopher Kung: Texas A&M Health Science Center
Qingguo Zhao: Texas A&M Health Science Center
W. Brian Saunders: Texas A&M University
Fei Liu: Texas A&M Health Science Center
Roland Kaunas: Texas A&M University
Carl A. Gregory: Texas A&M Health Science Center

Nature Communications, 2020, vol. 11, issue 1, 1-15

Abstract: Abstract Approximately 10% of fractures will not heal without intervention. Current treatments can be marginally effective, costly, and some have adverse effects. A safe and manufacturable mimic of anabolic bone is the primary goal of bone engineering, but achieving this is challenging. Mesenchymal stem cells (MSCs), are excellent candidates for engineering bone, but lack reproducibility due to donor source and culture methodology. The need for a bioactive attachment substrate also hinders progress. Herein, we describe a highly osteogenic MSC line generated from induced pluripotent stem cells that generates high yields of an osteogenic cell-matrix (ihOCM) in vitro. In mice, the intrinsic osteogenic activity of ihOCM surpasses bone morphogenic protein 2 (BMP2) driving healing of calvarial defects in 4 weeks by a mechanism mediated in part by collagen VI and XII. We propose that ihOCM may represent an effective replacement for autograft and BMP products used commonly in bone tissue engineering.

Date: 2020
References: Add references at CitEc
Citations:

Downloads: (external link)
https://www.nature.com/articles/s41467-020-16646-2 Abstract (text/html)

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:nat:natcom:v:11:y:2020:i:1:d:10.1038_s41467-020-16646-2

Ordering information: This journal article can be ordered from
https://www.nature.com/ncomms/

DOI: 10.1038/s41467-020-16646-2

Access Statistics for this article

Nature Communications is currently edited by Nathalie Le Bot, Enda Bergin and Fiona Gillespie

More articles in Nature Communications from Nature
Bibliographic data for series maintained by Sonal Shukla () and Springer Nature Abstracting and Indexing ().